Published date: 18 January 2018

Closed opportunity - This means that the contract is currently closed. The buying department may be considering suppliers that have already applied, or no suitable offers were made.


Closing: 26 January 2018

Contract summary

Industry

  • Pharmaceutical products - 33600000

Location of contract

North East, North West, Yorkshire and the Humber, East Midlands, West Midlands, East of England, London, South East, South West, Isle of Man, Channel Islands

Value of contract

£45,850,500

Procurement reference

tender_160028/644909

Published date

18 January 2018

Closing date

26 January 2018

Contract start date

1 August 2018

Contract end date

31 January 2020

Contract type

Supply contract

Procedure type

Open procedure

Any interested supplier may submit a tender in response to an opportunity notice.

Contract is suitable for SMEs?

Yes

Contract is suitable for VCSEs?

No


Description

NHS Pharmaceuticals 2017_2.
Period of framework agreement: The total maximum duration of the framework agreement to be no more than 36 months.
Potential periods of call-offs under the framework agreement:
CESW regions: 1.8.2018 to 28.2.2019 (7 months).
NWLN regions: 1.8.2018 to 31.7.2019 (12 months).
LSNE regions: 1.8.2018 to 31.1.2020 (18 months).
Products on the framework include (but are not necessarily limited to): Abacavir, Abiraterone, Anidulafungin, Atovaquone, Bosentan, Ciclesonide, Drospirenone/Ethinylestradiol, Enfurvitide, Ethinylestradiol/Norelgestromin, Exenatide, Ezetimibe, Iloprost, Ivabradine, Mycophenolic acid, Nitisinone, Olopatadine, Oseltamivir, Parecoxib, Pegfilgrastim, Pegvisomant, Pregabalin, Tadalafil, Tenofovir, Tigecycline, Valproic acid, Velaglucerase. Details of regions, presentation sizes and volumes are within the tender document set.


About the buyer

Address

2nd Floor, Rutland House
Runcorn
WA7 2ES
England

Email

david.ford1@nhs.net